136 related articles for article (PubMed ID: 37863030)
1. HATS off to KAT6A/B inhibitors: A new way to target estrogen-receptor-positive breast cancer.
Jeselsohn R; Polyak K
Cell Chem Biol; 2023 Oct; 30(10):1183-1185. PubMed ID: 37863030
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer.
Sharma S; Chung CY; Uryu S; Petrovic J; Cao J; Rickard A; Nady N; Greasley S; Johnson E; Brodsky O; Khan S; Wang H; Wang Z; Zhang Y; Tsaparikos K; Chen L; Mazurek A; Lapek J; Kung PP; Sutton S; Richardson PF; Greenwald EC; Yamazaki S; Jones R; Maegley KA; Bingham P; Lam H; Stupple AE; Kamal A; Chueh A; Cuzzupe A; Morrow BJ; Ren B; Carrasco-Pozo C; Tan CW; Bhuva DD; Allan E; Surgenor E; Vaillant F; Pehlivanoglu H; Falk H; Whittle JR; Newman J; Cursons J; Doherty JP; White KL; MacPherson L; Devlin M; Dennis ML; Hattarki MK; De Silva M; Camerino MA; Butler MS; Dolezal O; Pilling P; Foitzik R; Stupple PA; Lagiakos HR; Walker SR; Hediyeh-Zadeh S; Nuttall S; Spall SK; Charman SA; Connor T; Peat TS; Avery VM; Bozikis YE; Yang Y; Zhang M; Monahan BJ; Voss AK; Thomas T; Street IP; Dawson SJ; Dawson MA; Lindeman GJ; Davis MJ; Visvader JE; Paul TA
Cell Chem Biol; 2023 Oct; 30(10):1191-1210.e20. PubMed ID: 37557181
[TBL] [Abstract][Full Text] [Related]
3. The key roles of the lysine acetyltransferases KAT6A and KAT6B in physiology and pathology.
Wiesel-Motiuk N; Assaraf YG
Drug Resist Updat; 2020 Dec; 53():100729. PubMed ID: 33130515
[TBL] [Abstract][Full Text] [Related]
4. Discovery of N-(2-oxoethyl) sulfanilamide-derived inhibitors of KAT6A (MOZ) against leukemia by an isostere strategy.
Duan Y; Zhao Y; Li Z; Liu Z; Wang M; Wang X; Sun M; Song C; Yao Y
Eur J Med Chem; 2023 Nov; 260():115770. PubMed ID: 37651878
[TBL] [Abstract][Full Text] [Related]
5. Expression profiles and functional prediction of histone acetyltransferases of the MYST family in kidney renal clear cell carcinoma.
Liang F; Li X; Shen X; Yang R; Chen C
BMC Cancer; 2023 Jun; 23(1):586. PubMed ID: 37365518
[TBL] [Abstract][Full Text] [Related]
6. KAT6A, a chromatin modifier from the 8p11-p12 amplicon is a candidate oncogene in luminal breast cancer.
Turner-Ivey B; Guest ST; Irish JC; Kappler CS; Garrett-Mayer E; Wilson RC; Ethier SP
Neoplasia; 2014 Aug; 16(8):644-55. PubMed ID: 25220592
[TBL] [Abstract][Full Text] [Related]
7. Regulation of KAT6 Acetyltransferases and Their Roles in Cell Cycle Progression, Stem Cell Maintenance, and Human Disease.
Huang F; Abmayr SM; Workman JL
Mol Cell Biol; 2016 Jul; 36(14):1900-7. PubMed ID: 27185879
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth.
Baell JB; Leaver DJ; Hermans SJ; Kelly GL; Brennan MS; Downer NL; Nguyen N; Wichmann J; McRae HM; Yang Y; Cleary B; Lagiakos HR; Mieruszynski S; Pacini G; Vanyai HK; Bergamasco MI; May RE; Davey BK; Morgan KJ; Sealey AJ; Wang B; Zamudio N; Wilcox S; Garnham AL; Sheikh BN; Aubrey BJ; Doggett K; Chung MC; de Silva M; Bentley J; Pilling P; Hattarki M; Dolezal O; Dennis ML; Falk H; Ren B; Charman SA; White KL; Rautela J; Newbold A; Hawkins ED; Johnstone RW; Huntington ND; Peat TS; Heath JK; Strasser A; Parker MW; Smyth GK; Street IP; Monahan BJ; Voss AK; Thomas T
Nature; 2018 Aug; 560(7717):253-257. PubMed ID: 30069049
[TBL] [Abstract][Full Text] [Related]
9. Discovery of Benzoylsulfonohydrazides as Potent Inhibitors of the Histone Acetyltransferase KAT6A.
Leaver DJ; Cleary B; Nguyen N; Priebbenow DL; Lagiakos HR; Sanchez J; Xue L; Huang F; Sun Y; Mujumdar P; Mudududdla R; Varghese S; Teguh S; Charman SA; White KL; Katneni K; Cuellar M; Strasser JM; Dahlin JL; Walters MA; Street IP; Monahan BJ; Jarman KE; Sabroux HJ; Falk H; Chung MC; Hermans SJ; Parker MW; Thomas T; Baell JB
J Med Chem; 2019 Aug; 62(15):7146-7159. PubMed ID: 31256587
[TBL] [Abstract][Full Text] [Related]
10. Matrix stiffness-induced upregulation of histone acetyltransferase KAT6A promotes hepatocellular carcinoma progression through regulating SOX2 expression.
Zhao W; Mo H; Liu R; Chen T; Yang N; Liu Z
Br J Cancer; 2022 Jul; 127(2):202-210. PubMed ID: 35332266
[TBL] [Abstract][Full Text] [Related]
11. The role of MOZ/KAT6A in hematological malignancies and advances in MOZ/KAT6A inhibitors.
Su J; Wang X; Bai Y; Sun M; Yao Y; Duan Y
Pharmacol Res; 2021 Dec; 174():105930. PubMed ID: 34626770
[TBL] [Abstract][Full Text] [Related]
12. New KAT6 inhibitors induce senescence and arrest cancer growth.
Huang F
Synth Syst Biotechnol; 2018 Dec; 3(4):244-245. PubMed ID: 30417138
[TBL] [Abstract][Full Text] [Related]
13. Ada3 requirement for HAT recruitment to estrogen receptors and estrogen-dependent breast cancer cell proliferation.
Germaniuk-Kurowska A; Nag A; Zhao X; Dimri M; Band H; Band V
Cancer Res; 2007 Dec; 67(24):11789-97. PubMed ID: 18089809
[TBL] [Abstract][Full Text] [Related]
14. Histone Acetyltransferase KAT6A Upregulates PI3K/AKT Signaling through TRIM24 Binding.
Lv D; Jia F; Hou Y; Sang Y; Alvarez AA; Zhang W; Gao WQ; Hu B; Cheng SY; Ge J; Li Y; Feng H
Cancer Res; 2017 Nov; 77(22):6190-6201. PubMed ID: 29021135
[TBL] [Abstract][Full Text] [Related]
15. The Expression of Histone Acetyltransferase KAT6A in Non-small Cell Lung Cancer.
Partynska A; Piotrowska A; Pawelczyk K; Rzechonek A; Ratajczak-Wielgomas K; Podhorska-Okolow M; Dziegiel P
Anticancer Res; 2022 Dec; 42(12):5731-5741. PubMed ID: 36456139
[TBL] [Abstract][Full Text] [Related]
16. Histone acetyltransferases: challenges in targeting bi-substrate enzymes.
Wapenaar H; Dekker FJ
Clin Epigenetics; 2016; 8():59. PubMed ID: 27231488
[TBL] [Abstract][Full Text] [Related]
17. In Silico Study on the Interactions, Molecular Docking, Dynamics and Simulation of Potential Compounds from
Deshpande SH; Muhsinah AB; Bagewadi ZK; Ankad GM; Mahnashi MH; Yaraguppi DA; Shaikh IA; Khan AA; Hegde HV; Roy S
Molecules; 2023 Jan; 28(3):. PubMed ID: 36770785
[TBL] [Abstract][Full Text] [Related]
18. KAT6A and ENL Form an Epigenetic Transcriptional Control Module to Drive Critical Leukemogenic Gene-Expression Programs.
Yan F; Li J; Milosevic J; Petroni R; Liu S; Shi Z; Yuan S; Reynaga JM; Qi Y; Rico J; Yu S; Liu Y; Rokudai S; Palmisiano N; Meyer SE; Sung PJ; Wan L; Lan F; Garcia BA; Stanger BZ; Sykes DB; Blanco MA
Cancer Discov; 2022 Mar; 12(3):792-811. PubMed ID: 34853079
[TBL] [Abstract][Full Text] [Related]
19. KAT6A is associated with sorafenib resistance and contributes to progression of hepatocellular carcinoma by targeting YAP.
Jin Y; Yang R; Ding J; Zhu F; Zhu C; Xu Q; Cai J
Biochem Biophys Res Commun; 2021 Dec; 585():185-190. PubMed ID: 34808502
[TBL] [Abstract][Full Text] [Related]
20. Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patients.
Nakata T; Takashima S; Shiotsu Y; Murakata C; Ishida H; Akinaga S; Li PK; Sasano H; Suzuki T; Saeki T
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):455-60. PubMed ID: 14623544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
